NCT03292653View on ClinicalTrials.gov

Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure

PHASE2TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 4, 2017

Primary Completion Date

August 17, 2019

Study Completion Date

August 17, 2019

Conditions
Cardiac Failure Aggravated
Interventions
DRUG

Sotagliflozin

Pharmaceutical form: Tablet; Route of administration: Oral

DRUG

Placebo

Pharmaceutical form: Tablet; Route of administration: Oral

Trial Locations (6)

44195

Investigational Site Number 8400002, Cleveland

55905

Investigational Site Number 8400007, Rochester

92037

Investigational Site Number 8400005, La Jolla

06510

Investigational Site Number 8400001, New Haven

M5G 2N2

Investigational Site Number 1240001, Toronto

9713 GZ

Investigational Site Number 5280001, Groningen

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Lexicon Pharmaceuticals

INDUSTRY